A minority of studies used the standard three-point MACE endpoint, and many tweaked their endpoints along the way.
The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with ...
Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback